Alterations in gut microbiome and metabolite profile of patients with Schistosoma japonicum infection.
Disease progression
Gut microbiome
Metabolite profile
Schistosoma japonicum infection
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
received:
28
05
2023
accepted:
14
09
2023
medline:
9
10
2023
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
Schistosoma infection is a significant public health issue, affecting over 200 million individuals and threatening 700 million people worldwide. The species prevalent in China is Schistosoma japonicum. Recent studies showed that both gut microbiota and metabolome are closely related to schistosomiasis caused by S. japonicum, but clinical study is limited and the underlying mechanism is largely unclear. This study aimed to explore alterations as well as function of gut microbiota and metabolite profile in the patients with S. japonicum infection. This study included 20 patients diagnosed with chronic schistosomiasis caused by S. japonicum, eight patients with advanced schistosomiasis caused by S. japonicum and 13 healthy volunteers. The fresh feces of these participators, clinical examination results and basic information were collected. 16S ribosomal RNA gene sequencing was used to investigate gut microbiota, while ultraperformance liquid chromatography-mass spectrometry (UHPLC-MS) was applied to explore the metabolome of patients in different stages of schistosomiasis. The study found that gut microbiota and metabolites were altered in patients with different stages of S. japonicum infection. Compared with healthy control group, the gut microbial diversity in patients with chronic S. japonicum infection was decreased significantly. However, the diversity of gut microbiota in patients with chronic schistosomiasis was similar to that in patients with advanced schistosomiasis. Compared with uninfected people, patients with schistosomiasis showed decreased Firmicutes and increased Proteobacteria. As disease progressed, Firmicutes was further reduced in patients with advanced S. japonicum infection, while Proteobacteria was further increased. In addition, the most altered metabolites in patients with S. japonicum infection were lipids and lipid-like molecules as well as organo-heterocyclic compounds, correlated with the clinical manifestations and disease progress of schistosomiasis caused by S. japonicum. This study suggested that the gut microbiota and metabolome altered in patients in different stages of schistosomiasis, which was correlated with progression of schistosomiasis caused by S. japonicum. This inter-omics analysis may shed light on a better understanding of the mechanisms of the progression of S. japonicum infection and contribute to identifying new potential targets for the diagnosis and prognosis of S. japonicum infection. However, a large sample size of validation in clinic is needed, and further study is required to investigate the underlying mechanism.
Sections du résumé
BACKGROUND
BACKGROUND
Schistosoma infection is a significant public health issue, affecting over 200 million individuals and threatening 700 million people worldwide. The species prevalent in China is Schistosoma japonicum. Recent studies showed that both gut microbiota and metabolome are closely related to schistosomiasis caused by S. japonicum, but clinical study is limited and the underlying mechanism is largely unclear. This study aimed to explore alterations as well as function of gut microbiota and metabolite profile in the patients with S. japonicum infection.
METHODS
METHODS
This study included 20 patients diagnosed with chronic schistosomiasis caused by S. japonicum, eight patients with advanced schistosomiasis caused by S. japonicum and 13 healthy volunteers. The fresh feces of these participators, clinical examination results and basic information were collected. 16S ribosomal RNA gene sequencing was used to investigate gut microbiota, while ultraperformance liquid chromatography-mass spectrometry (UHPLC-MS) was applied to explore the metabolome of patients in different stages of schistosomiasis.
RESULTS
RESULTS
The study found that gut microbiota and metabolites were altered in patients with different stages of S. japonicum infection. Compared with healthy control group, the gut microbial diversity in patients with chronic S. japonicum infection was decreased significantly. However, the diversity of gut microbiota in patients with chronic schistosomiasis was similar to that in patients with advanced schistosomiasis. Compared with uninfected people, patients with schistosomiasis showed decreased Firmicutes and increased Proteobacteria. As disease progressed, Firmicutes was further reduced in patients with advanced S. japonicum infection, while Proteobacteria was further increased. In addition, the most altered metabolites in patients with S. japonicum infection were lipids and lipid-like molecules as well as organo-heterocyclic compounds, correlated with the clinical manifestations and disease progress of schistosomiasis caused by S. japonicum.
CONCLUSIONS
CONCLUSIONS
This study suggested that the gut microbiota and metabolome altered in patients in different stages of schistosomiasis, which was correlated with progression of schistosomiasis caused by S. japonicum. This inter-omics analysis may shed light on a better understanding of the mechanisms of the progression of S. japonicum infection and contribute to identifying new potential targets for the diagnosis and prognosis of S. japonicum infection. However, a large sample size of validation in clinic is needed, and further study is required to investigate the underlying mechanism.
Identifiants
pubmed: 37798771
doi: 10.1186/s13071-023-05970-3
pii: 10.1186/s13071-023-05970-3
pmc: PMC10552355
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
346Subventions
Organisme : National Natural Science Foundation of China
ID : 81771722
Organisme : Key Research and Development Plan of Hunan Province
ID : 2021SK2032
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Nutrients. 2022 May 28;14(11):
pubmed: 35684059
Anal Chem. 2021 May 11;93(18):7110-7117
pubmed: 33909401
Res Rep Trop Med. 2019 Dec 31;10:153-163
pubmed: 32099508
Rapid Commun Mass Spectrom. 2006;20(20):3023-9
pubmed: 16986207
Cell Metab. 2017 Jan 10;25(1):43-56
pubmed: 28094011
J Invest Surg. 2015;28(5):236-44
pubmed: 26290958
J Nucleic Acids. 2010 Jul 25;2010:
pubmed: 20725615
Hepatol Int. 2019 Nov;13(6):748-756
pubmed: 31515740
Int Immunopharmacol. 2003 Feb;3(2):197-207
pubmed: 12586601
Parasitol Res. 2015 Jan;114(1):17-27
pubmed: 25403379
Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9
pubmed: 26979502
Nat Rev Mol Cell Biol. 2019 Jun;20(6):353-367
pubmed: 30814649
Parasit Vectors. 2022 Nov 7;15(1):413
pubmed: 36345042
Biophys Rev. 2012 Dec;4(4):283-290
pubmed: 28510205
Immunology. 2017 Aug;151(4):363-374
pubmed: 28542929
Front Microbiol. 2020 Jul 14;11:1517
pubmed: 32760365
Ann Transl Med. 2018 Dec;6(24):472
pubmed: 30740403
Front Microbiol. 2019 Mar 05;10:352
pubmed: 30891012
Acta Trop. 2015 Mar;143:51-7
pubmed: 25559046
Infect Dis Poverty. 2021 Mar 26;10(1):43
pubmed: 33771232
J Neural Transm (Vienna). 2018 Nov;125(11):1707-1717
pubmed: 30255284
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
Parasite. 2021;28:1
pubmed: 33416489
Sci Rep. 2021 Apr 28;11(1):9207
pubmed: 33911145
J Bioenerg Biomembr. 2018 Feb;50(1):11-19
pubmed: 29243009
J Clin Biochem Nutr. 2010 Mar;46(2):177-85
pubmed: 20216951
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2021 Jun 22;33(3):225-233
pubmed: 34286522
World J Gastroenterol. 2013 Feb 28;19(8):1230-8
pubmed: 23482848
World J Gastroenterol. 2017 Aug 21;23(31):5700-5712
pubmed: 28883695
Infect Immun. 2020 Jul 21;88(8):
pubmed: 32341115
Curr Opin Microbiol. 2016 Aug;32:59-65
pubmed: 27200489
Acta Oncol. 2012 Mar;51(3):301-10
pubmed: 22283492
Parasitol Res. 2015 Jan;114(1):85-90
pubmed: 25287714
Ital J Gastroenterol. 1990 Aug;22(4):205-13
pubmed: 2131947
Biochim Biophys Acta. 2013 Mar;1831(3):543-54
pubmed: 22960354
J Innate Immun. 2013;5(4):324-35
pubmed: 23571667
Lancet. 2006 Sep 23;368(9541):1106-18
pubmed: 16997665
Sensors (Basel). 2011;11(2):1744-55
pubmed: 22319379
Adv Parasitol. 2016;92:409-34
pubmed: 27137454
Biochemistry. 2005 Dec 6;44(48):15944-52
pubmed: 16313198
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2023 Jan 5;34(6):559-565
pubmed: 36642895
Front Microbiol. 2017 Nov 21;8:2248
pubmed: 29250037
Front Immunol. 2020 Oct 08;11:569727
pubmed: 33162984
J Clin Exp Hepatol. 2020 Jul-Aug;10(4):275-283
pubmed: 32655229
Sci Rep. 2021 Dec 7;11(1):23568
pubmed: 34876650
PLoS Negl Trop Dis. 2011 Nov;5(11):e1399
pubmed: 22102924
Cell Host Microbe. 2017 Jul 12;22(1):25-37.e6
pubmed: 28704649